Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thermostable trivalent filovirus vaccine
- Development stage
- Unknown
- Lead developer
- Soligenix
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **thermostable trivalent filovirus vaccine** is an investigational **recombinant protein subunit vaccine** being developed to provide protection against multiple medically important filoviruses while reducing reliance on cold-chain logistics. Available public materials describe it as a **lyophilized, thermostabilized trivalent formulation** containing glycoprotein antigens from **Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus**, with formulation work supported by Soligenix's ThermoVax technology and academic collaborators including the University of Hawaii at Manoa. Its intended mechanism is to present viral envelope glycoprotein antigens to the immune system and induce protective humoral immune responses against these filoviruses; in some reported preclinical formulation studies, the candidate was tested with the nanoemulsion adjuvant CoVaccine HT. The program appears to have remained in **preclinical development** rather than advancing to approved clinical use.
- Other names
- thermostabilized trivalent filovirus vaccinetrivalent thermostabilized Ebola vaccine
02
Targets
BDBV GP (Bundibugyo ebolavirus glycoprotein)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on thermostable trivalent filovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thermostable trivalent filovirus vaccine.